The AAM’s new CEO, Dan Leonard, has set out his priorities for the industry association, highlighting current industry challenges as well as throwing light on how generics can be the “bridge” to a COVID-19 vaccine.

In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.

Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.